Original Publication Date: 1 March, 2014
Publication / Source: Future Oncology
Authors: Alfredo Tartarone, Rosa Lerose, Raffaele Ardito
Small cell lung cancer (SCLC) represents approximately 13% of all newly diagnosed lung cancers. SCLC is a very aggressive disease characterized by early locoregional and distant metastases. The median survival is 14–16 months for patients with limited disease and 8–11 months for those with extensive disease, with 20–40% of patients with limited disease and 5% of patients with extensive disease alive at 2 years.